Activation of cytokines corroborate with development of inflammation and autoimmunity in thromboangiitis obliterans patients

Clinical and Experimental Immunology

Volumn 170, Issue 1, 2012, Pages 28-35

  Dellalibera Joviliano, R ^a,b   Joviliano, E E ^b   Silva, J S ^b   Evora, P R B ^b  

^a University Center UNIFAFIBE   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Autoimmune disease; Buerger's disease; Cytokines; Inflammation; Thromboangiitis obliterans

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 23; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; AUTOIMMUNITY; BLOOD SAMPLING; BUERGER DISEASE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; INFLAMMATION; MALE; PATHOGENESIS; PRIORITY JOURNAL; SMOKING; TH1 CELL; TH2 CELL;

ADULT; AUTOIMMUNITY; CASE-CONTROL STUDIES; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INFLAMMATION; INTERLEUKIN-1; INTERLEUKIN-17; INTERLEUKIN-23; INTERLEUKIN-4; MALE; MIDDLE AGED; SMOKING; STATISTICS, NONPARAMETRIC; T-LYMPHOCYTES, HELPER-INDUCER; THROMBOANGIITIS OBLITERANS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84865691863     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2012.04624.x     Document Type: Article

References (33)

1. Olin JW, Shih A. Thromboangiitis obliterans (Buerger's disease). Curr Opin Rheumatol 2006; 18:18-24.
2. Chochola M, Márová K, Linhart A. Buerger's disease. Cas Lek Cesk 2006; 145:358-62.
3. Lazarides MK, Georgiadis GS, Papas TT etal. Diagnostic criteria and treatment of Buerger's disease: a review. Int J Low Extrem Wounds 2006; 5:89-95.
4. Olin JW, Young JR, Graor RA etal. The changing clinical spectrum of thromboangiitis obliterans (Buerger's disease). Circulation 1990; 82:IV3-8.
5. Kobayashi M, Nishikimi N, Komori K. Current pathological and clinical aspects of Buerger's disease in Japan. Ann Vasc Surg 2006; 20:148-56.
6. Quintas A, Albuquerque R. Buerger's disease: current concepts. Rev Port Cir Cardiotorac Vasc 2008; 15:31-8.
7. Tanaka K. Pathology and pathogenesis of Buerger's disease. Int J Cardiol 1998; 1/66:S237-42.
8. Makita S, Nakamura M, Murakami H etal. Impaired endothelium-dependent vasorelaxation in peripheral vasculature of patients with thromboangiitis obliterans (Buerger's disease). Circulation 1996; 1/94:II211-5.
9. Shionoya S. Diagnostic criteria of Buerger's disease. Int J Cardiol 1998; N66:243-5.
10. Sasajima T, Kubo Y, Inaba M, Goh K, Azuma N. Role of infrainguinal bypass in Buerger's disease: an eighteen-year experience. Eur J Vasc Endovasc Surg 1997; 13:186-92.
11. Powrie F, Coffman RL. Cytokine regulation of T-cell function: potential for therapeutic intervention. Immunol Today 1993; 14:270-4.
12. Quintas A, Albuquerque R. [Buerger's disease: current concepts.] Rev Port Cir Cardiotorac Vasc 2008; 15:33-40.
13. Tanaka K. Pathology and pathogenesis of Buerger's disease. Int J Cardiol 1998; 66 (Suppl. 1):S237-42.
14. Joviliano EE, Dellalibera-Joviliano R, Dalio MB etal. Etiopathogenesis, clinical diagnosis and treatment of thromboangiitis obliterans-current practices. Int J Angiol 2009; 18:119-25.
15. Dellalibera-Joviliano R, Joviliano EE, Evora PR. Determination of kininogens levels and kallikrein/kininase II activities in patients with thromboangiitis obliterans. Scand J Immunol 2010; 72:128-33.
16. Dellalibera-Joviliano R, Jacob-Ferreira AL, Joviliano EE, Tanus JE, Evora PR. Imbalanced matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 activities in patients with thromboangiitis obliterans. Vasc Med 2012; 17:73-8.
17. Slavov ES, Stanilova SA, Petkov DP, Dobreva ZG. Cytokine production in thromboangiitis obliterans patients: new evidence for an immune-mediated inflammatory disorder. Clin Exp Rheumatol 2005; 23:219-26.
18. Matsui K, Yoshioka T, Murakami Y, Takahashi M, Shimada K, Ikeda U. Serum concentrations of vascular endothelial growth factor and monocyte-colony stimulating factor in peripheral arterial disease. Circ J 2003; 67:660-2.
19. Halacheva K, Gulubova MV, Manolova I, Petkov D. Expression of ICAM-1, VCAM-1, E-selectin and TNF-alpha on the endothelium of femoral and iliac arteries in thromboangiitis obliterans. Acta Histochem 2002; 104:177-84.
20. Arkkila PE. Thromboangiitis obliterans (Buerger's disease). Orphanet J Rare Dis 2006; 27:14.
21. Adar R, Papa MZ, Halpern Z, Mozes M etal. Cellular sensitivity to collagen in thromboangiitis obliterans. N Engl J Med 1983; 308:1113-6.
22. de Moerloose P, Jeannet M, Mirimanoff P, Bouvier CA. Evidence for an HLA-linked resistance gene in Buerger's disease. Tissue Antigens 1979; 14:169-73.
23. Kobayashi M, Ito M, Nakagawa A, Nishikimi N, Nimura Y. Immunohistochemical analysis of arterial wall cellular infiltration in Buerger's disease (endarteritis obliterans). J Vasc Surg 1999; 29:451-8.
24. Papa M, Bass A, Adar R etal. Autoimmune mechanisms in thromboangiitis obliterans (Buerger's disease): the role of tobacco antigen and the major histocompatibility complex. Surgery 1992; 111:527-31.
25. Toussirot E. The IL23/Th17 pathway as a therapeutic target in chronic inflammatory diseases. Inflamm Allergy Drug Targets 2012; 11:159-68.
26. Astry B, Harberts E, Moudgil KD. A cytokine-centric view of the pathogenesis and treatment of autoimmune arthritis. J Interferon Cytokine Res 2011; 31:927-40.
27. Tang C, Chen S, Qian H, Huang W. Interleukin-23: as a drug target for autoimmune inflammatory diseases. Immunology 2012; 135:112-24.
28. Stockinger B, Veldhoen M. Lymphocyte activation/lymphocyte effector functions. Curr Opin Immunol 2007; 19:281-6.
29. Dong C. TH17 cells in development: an updated view of their molecular identity and genetic programming. Nat Rev Immunol 2008; 8:337-48.
30. Manel N, Unutmaz D, Littman DR. The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat. Nat Immunol 2008; 9:641-9.
31. Ouyang W, Kolls JK, Zheng Y. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity 2008; 28:454-67.
32. Bettelli E, Carrier Y, Gao W etal. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006; 441:235-8.
33. Korn T, Bettelli E, Gao W etal. IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature 2006; 448:484-7.